Clinical Trials Logo

Type 1 Diabetes clinical trials

View clinical trials related to Type 1 Diabetes.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06338072 Active, not recruiting - Type 1 Diabetes Clinical Trials

Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1).

DIABETEXX/1
Start date: March 3, 2024
Phase:
Study type: Observational

The aim of this observational study is to assess the effectiveness of automatic insulin infusion in responding to changes in insulin sensitivity throughout various phases of the menstrual cycle in a cohort of reproductive-aged women with type 1 diabetes, using an advanced closed-loop system. By gaining insights into both the limitations and effectiveness of this adaptation, we aim to inform the enhancement of control algorithms and learning strategies within closed-loop systems. This research is especially vital for addressing the distinct challenges that women commonly encounter in maintaining glycemic control.

NCT ID: NCT06048757 Active, not recruiting - Type 1 Diabetes Clinical Trials

Mobile Application-delivered Resistance Program for Children and Adolescents With Type 1 Diabetes (Diactive-1)

Diactive-1
Start date: August 20, 2023
Phase: N/A
Study type: Interventional

This project involves a two-arm randomized controlled trial (RCT) designed to assess the feasibility, acceptability, and preliminary efficacy of a mobile application aimed at prescribing resistance training for children and adolescents with type 1 diabetes (Diactive-1). The program will span 24 weeks, with a minimum weekly frequency of 3 sessions. The researchers aim to recruit 52 participants but will enroll additional participants to account for potential withdrawals and ensure compliance with the desired sample size. The primary objective of the study is to evaluate the impact of the Diactive-1 mobile application on insulin requirements in children and adolescents with Type 1 Diabetes. Additionally, the researchers will investigate the effects of the Diactive-1 program on secondary parameters such as glycemic control, cardiometabolic indicators, physical fitness, and daily physical activity, among others. The hypothesis posits that personalized training through a mobile application, primarily focusing on muscular strength, will effectively reduce the daily insulin dosage in children and adolescents with type 1 diabetes.

NCT ID: NCT06017089 Active, not recruiting - Type 1 Diabetes Clinical Trials

The Pediatric Artificial Pancreas Automated Initialization Trial

PEDAP-AI
Start date: November 10, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to obtain safety data and exploratory glycemic control data from use of an at-home closed loop control (CLC) system (t:slim X2 with Control-IQ Technology) with periodic parameter adjustments driven by an AI-based Advisor system in young children with Type 1 Diabetes. The main endpoints this study aims to answer is the safety and efficacy of the use of the AI-driven pump parameters. Participants will use the study system (pump and Continuous Glucose Monitor) in closed-loop mode for eight weeks.

NCT ID: NCT06006468 Active, not recruiting - Type 1 Diabetes Clinical Trials

Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult ONset

INCEPTiON
Start date: February 1, 2023
Phase:
Study type: Observational

Little is known about how type 1 diabetes or coeliac disease develop in adults. Studies following children at risk of type 1 diabetes from birth have shown that the marker of type 1 diabetes autoimmunity (antibodies against the insulin producing cells in the pancreas (Glutamic Acid Decarboxylase Autoantibodies (GADA), Insulin Autoantibodies (IAA), Zinc Transporter 8 Autoantibodies (ZnT8), Anti-tyrosine phosphatase-like insulinoma antigen 2 (IA-2))) can develop many years before glucose levels are raised and diabetes is diagnosed. In adults, it is unclear when antibodies develop in relation to high blood glucose levels and the diagnosis of type 1 diabetes. Similarly in coeliac disease it is unclear to what degree Tissue transglutaminase autoantibodies (TTG) in adults proceed the development of clinically diagnosed disease. The investigators will use samples collected and stored in The Exeter 10,000 volunteer research bank (https://exetercrfnihr.org/about/exeter-10000/) and so no new sample collection is required. This includes ~8000 participants with no history of coeliac disease or diabetes at recruitment. The investigators wish to determine prevalence of autoantibodies in the background adult population split by the highest genetic risk for type 1 diabetes and separately coeliac disease compared to a control population with lower genetic risk for these conditions. The investigators will also evaluate the proportion of these identified cases progressing to clinically diagnosed disease. The aim of this study is to investigate evidence of autoimmunity prior to disease development and generate pilot data for the validity of screening based on genetic predisposition for type 1 diabetes and coeliac disease.

NCT ID: NCT05742243 Active, not recruiting - Type 1 Diabetes Clinical Trials

Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes

IAA
Start date: February 13, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test whether the combination of two safe immune therapies called abatacept and nasal insulin can preserve pancreas function in recently-diagnosed type 1 diabetes. When type 1 diabetes is first diagnosed, the pancreas is still able to make small amounts of insulin, which helps control glucose levels. Preserving pancreas function can make glucose control easier and reduce the need to use injected insulin. Participants will be asked to inject abatacept under their skin once per week and inhale nasal insulin or nasal placebo using a spray for 10 consecutive days initially and twice per week thereafter. The treatment period is for 48 weeks, with another 48-week follow-up period.

NCT ID: NCT05671679 Active, not recruiting - Type 1 Diabetes Clinical Trials

Supporting Meal Management in Type 1 Diabetes

SUMMIT1
Start date: March 27, 2023
Phase: N/A
Study type: Interventional

Carbohydrate count marks the cornerstone of Type 1 Diabetes management. Eventhough it is a crucial task, it is burdensome and prone to error. Therefore, the investigators want to explore the effect that SNAQ, a food analyser app would have in glycaemic control by facilitating the task of carbohydrate estimation.

NCT ID: NCT05662826 Active, not recruiting - Type 1 Diabetes Clinical Trials

Avatar-based Social Physical Activity

ASPA
Start date: January 17, 2023
Phase: N/A
Study type: Interventional

This study is testing program where teens with type 1 diabetes play Meta Quest 2 virtual reality exercise games and talk, act, and paint about physical activity in virtual meetings with their peers and young adult role models. The outcomes are feasibility and user satisfaction.

NCT ID: NCT05614089 Active, not recruiting - Type 1 Diabetes Clinical Trials

Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings

HumAn-1
Start date: March 15, 2023
Phase: Phase 4
Study type: Interventional

The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g. NPH or premixed 70/30) among youth living with type 1 diabetes (T1D) in low resource settings.

NCT ID: NCT05577169 Active, not recruiting - Type 1 Diabetes Clinical Trials

Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes

Start date: September 14, 2022
Phase: N/A
Study type: Interventional

Adolescence presents a challenging time for type 1 diabetes management, and despite a multitude of studies aimed at increasing disease compliance in this age group, none have been deemed superior. The purpose of this study is to incorporate mindfulness skills in with diabetes education sessions for adolescents with type 1 diabetes and study if this translates to improved outcomes in glycemic control, patient satisfaction, and mental wellness.

NCT ID: NCT05564481 Active, not recruiting - Type 1 Diabetes Clinical Trials

Research on Optimizing the Use of Technology With Education

ROUTE-T1D
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Consistent use of continuous glucose monitors (CGM) has the potential to improve glycemic control and related type 1 diabetes (T1D) health outcomes, however young adolescents with T1D are the least likely age group to begin and sustain use of CGM. The proposed study will conduct a feasibility trial of a behavioral intervention designed to optimize use of CGM in adolescents specifically targeting underrepresented populations in diabetes technology research.